Skip to content

Author

Qing-Bo Liu

We have 2 of 95 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Hypoxia-activated 2-nitroimidazole-brusatol carbonate prodrugs for enhanced gastric cancer therapy with reduced systemic toxicity.

This work describes the first hypoxia-activated BST prodrug with potent in vivo efficacy and improved safety, providing a targeted delivery strategy and a promising lead agent for gastric cancer treatment.

Ji-Chong Li, Xue-Lan Ma, Zi-Jian Liu et al. · 0 citations
Jul 2026

Targeting Cys328 in the STAT3 DNA-binding domain with the germacrane-type sesquiterpene lactone SCP-7 inhibits colorectal Cancer growth in vitro and in vivo.

Findings identify SCP-7 as a novel covalent inhibitor targeting the STAT3-DBD with potent anti-CRC activity in vitro and in vivo, providing a promising lead compound for STAT3-targeted cancer therapy.

Yuan-Qing Li, Guxue Zhang, Yuhang Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.